P/E (TTM) ~28.3x - 28.9x HIGH ⚠️. Despite the price drop, the market values ​​it highly. Forward P/E ~18.5x - 19.1x GOOD ✅. It is at a 5-year low on this metric. Free Cash Flow ~$6.5 billion EXCELLENT ✅. Cash generating machine. ROE ~17.6% EXCELLENT ✅. Meets your 14.5% criterion. Debt/Equity ~0.23 (23%) PERFECT ✅. Extremely low debt. PEG Ratio ~2.01 HIGH ⚠️. Growth is expensive relative to the current price. Dividend Yield ~2.35% EXCELLENT ✅. Dividend aristocrat (50+ years of growth). Cash on Hand ~$7.7 billion EXCELLENT ✅. Huge liquidity. FCF Margin ~20.8% HIGH ✅. Converts 1/5 of revenue into pure cash. Quick Ratio ~1.24 GOOD ✅. Healthy liquidity. Inst. Ownership ~76% HIGH ✅. Great trust from funds. Current Ratio ~1.70 GOOD ✅. Stable balance sheet. Analyst DCF $92.08 - $93.05 OVERVALUED ⚠️. Current price ($106) is above DCF value. Wall St Target $136.32 Potential growth of ~28% from current levels. Gross Margin ~57.1% GOOD ✅ Sales Growth ~4.4% Altman Z-Score ~3.53 SUPER SAFE ✅. Financially unshakable. and on January 23, 2026, immediately after the stock crashed after the report, Abbott CEO and Chairman Robert B. Ford himself aggressively entered the market. Here are the details of this purchase that confirm your observation: Insider Purchase Details (Robert B. Ford) Date of Purchase: January 23, 2026 Number of Shares Purchased: 18,800 shares. Average Price: ~$107.13 per share. Total Amount: $2,013,966. After the Purchase: He now owns directly and indirectly (through the Ford Family Trust) over 469,500 shares, worth over $50 million. Why is this critical to you as an investor? First Purchase of the Year: This is Ford's first open market purchase in quite some time. CEOs usually get stock as bonuses, but when they take out $2 million of their own cash to buy into the market, it means only one thing: they believe the stock is grossly undervalued. "Put your money where your mouth is": Ford made this purchase just as Wall Street analysts were lowering their targets due to weak sales in the Nutrition segment. He literally bet against analysts' pessimism. Historical success: Statistics show that after insider purchases by Robert Ford, ABT shares usually have an average return of about 15.4% over the next 3 months.

The price corrects significantly following the quarterly earnings report and drops until it reaches the long-term support highlighted in blue, where the price halts its decline. A rebound from this support level is very likely, as it has been providing support for the price for the past 10 years.

ABT Earnings Signal | 2026-01-21 Direction: BUY CALLS Strike: $117.00 Expiry: Jan 23, 2026 Entry: ~$4.85 Target: $6.50 (+34%) Extended Target: $7.50 (+55%) Stop Loss: $3.88 (-20%) 🧠 Why This Trade Katy AI Forecast: Bullish price path toward $123+ despite neutral label Technical Setup: Deeply oversold stochastic (8.2) → bounce potential News Catalyst: CE Mark approval for new product (positive sentiment) Options Flow: Slight call bias (PCR 0.83), unusual activity at $130 calls ⚠️ Key Risks Low overall confidence (55%) Weak earnings beat history (25%) High IV → possible post-earnings IV crush Light volume = limited market conviction 💡 Position Management Use small size only (≤2%) Tight stop required Consider quick profit-taking if target hits pre-expiry 🚨 IMPORTANT NOTES Low conviction due to Katy AI's 50% confidence and conflicting technical signals. Earnings beat history is poor (25%), increasing risk of miss. High IV in options may lead to premium decay post-earnings; consider exiting before expiry. Monitor volume for confirmation—current light volume indicates weak market participation.

Abbott is already a $220 billion heavyweight in medical devices, but its reach goes well beyond that.. The company brings in billions from diagnostics, nutrition, and established pharmaceuticals, making it one of the most diversified names in the sector Now it’s buying Exact Sciences, the maker of the Cologuard colorectal cancer test, in a $21 billion all cash deal expected to close in Q2 2026. It’s a clear signal that diagnostics is becoming a bigger priority Diagnostics as a growth engine Exact isn’t a small add on. Cologuard is one of the most successful at home tests ever, pulling in more than $2 billion a year with double-digit growth. Its recurring revenue comes from something simple but powerful: people actually stick to screening For Abbott, this brings in a high margin diagnostics line with strong repeat demand and plenty of room to cross-sell. The company wants to build a leading cancer diagnostics business, and this is a big step toward that Distribution, brand, and recurring use Cologuard works cuz providers trust it, patients know it, and it’s easy to use. Abbott is strong in all those areas With Abbott’s global distribution, the test can reach far more patients. The company can bundle it with its existing diagnostics portfolio and expand into other cancer screening categories Exact has been working on. It’s similar to how Abbott scaled FreeStyle Libre into a market leader. A rare deal that offers both value and growth Cancer screening brings steady repeat demand. Diagnostics revenue is stable. And Cologuard has brand recognition most tests never build. Abbott has the financial muscle and sales network to take it worldwide Exact is on track for more than $3 billion in revenue this year. Once the deal closes, it should push Abbott’s diagnostics segment above $12 billion a year. Exact’s big drop in Q4 FY24 margins came from one time charges, impairments, and restructuring not from the core business. Gross margins stayed consistent, and operating margins bounced right back Why it matters ?? Large healthcare companies are shifting toward buying proven products with predictable demand instead of pouring money into untested R&D bets. Recent examples include: Johnson & Johnson buying Shockwave Medical (~$13 billion) for fast-growing cardiovascular technology Danaher buying Abcam (~$6 billion) to expand its antibody and reagent work Thermo Fisher buying Olink (~$3 billion) to grow its proteomics tools In markets full of uncertainty, established players are choosing reliability over moonshots. Abbott can afford to keep doing deals like this, with room for up to $30 billion in debt funded acquisitions thanks to low leverage and $7 billion in annual free cash flow

NYSE:ABT is looking bullish and has a long term target of 192$, being a long term trade, I will place my stop at 115$ (weekly close). PS. My view only not financial advice!

ABT is the stock ticker for Abbott Laboratories, a global healthcare company that develops and sells a wide range of health products. Its business is divided into four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company's products include generic pharmaceuticals, diagnostic systems, infant and adult nutrition products, and medical devices for cardiovascular and diabetes care, as well as neuromodulation and vascular products.

Enter: NYSE:ABT OCT 31 2025 $135 CALLS Buy in Price: $2.75 - $3.35 Take Profit: $3.69 Stop Bleeding: $2.42 ROI Potential: 34% Exit Within: 132 Minutes

Trading Idea: NYSE:ABT (Abbott Laboratories) - Long Setup 🎯 Idea: LONG ⏰ Timeframe: Daily 📊 Pattern: Bullish Breakout from Consolidation Fundamental Context: Fundamental Score: 5/9 (Neutral). Business: Global Healthcare Leader (Medical Devices, Diagnostics, Nutrition). Growth: Weak Revenue + Strong Net Income Growth YoY. Balance Sheet: Excellent (Debt Score: 10/10). Very strong financial health. Valuation: Fairly Valued on P/E; Overvalued on P/B and P/S. Technical Setup: Trend (D1): Bullish ✅ Catalyst: Recent RSI2 Connors Buy Signal (confirmed oversold bounce). Entry: $135.70 (Break above consolidation resistance). Stop Loss (SL): $130.00 (Below key support and the 50-period SMA). Take Profit (TP): $148.00 (Previous resistance target). Momentum: RSI in bullish territory, MACD showing positive momentum. Risk Management: Risk/Reward (R:R): 1:2.2 Position size based on the risk between entry and stop. Summary: A breakout play on a high-quality healthcare giant with a pristine balance sheet and strong earnings growth, targeting a move to the next resistance level. ⚠️ Disclaimer: Not Financial Advice This analysis is for educational and informational purposes only. It is NOT a recommendation to buy or sell any security. Conduct your own research (DYOR) before making any investment decisions. You are solely responsible for your own trades and investments. Past performance is never indicative of future results. Trading involves significant risk of loss and is not suitable for all investors. #TradingView #ABT #Long #Healthcare #Medical #Dividend #RSI2 #Connors #Breakout #TradingSetup

Hello everyone, This is the last one for today. ABT Abbott Laboratories . What they do? Abbott Laboratories offers pharmaceutical, diagnostic, and nutritional products, as well as medical devices to treat cardiovascular disease and diabetes care products. Operating internationally, the company was founded in 1888 and has its headquarters in Chicago, Illinois. Financial Infos: Market Cap : 236.77 B Revenue : 43.11 B EPS : 7.9964 P/E Ratio : 17.01 Dividend Yield : %1.71 Technical Part: There is a possible break out the Down trend to up and we could expect to continue trend to Up. Volume data is also supports this trend. If it could achive to stay above 134.90 - 135.00 then i would expect to go up and hit 143.50 - 144.00. For other support and resistance levels you can watch the FIB levels that i draw in Chart. Short term i beleive you can make some small gain from ABT. I have already added ABT to my watch list for next week ;) This is just my thinking and it is not invesment suggestion , please do not make any decision with my anaylsis. Have a lovely Weekend to all.

Technical analysis of the company. According to financial indicators, the company is currently undervalued and is supported by SMA200. The target price for the company is $142.